START UP, PREPARATION, AND TEST ENROLLMENT FOR THE TIMING OF DELIVERY (TIME) AIM OF THE STUDY OF PREGNANCY AND NEONATAL HEALTH (SPAN)

尤尼斯·肯尼迪·施莱弗国家儿童健康与人类发展研究所(NICHD)的内部人口健康研究部(DIPHR)设计并进行了原创性的流行病学、行为和生物统计学研究，涵盖了几个研究领域，如人类生殖和发育、怀孕和相关并发症、儿科和青少年健康和行为，以及与我们的使命相关的方法学研究。该司由三个内部研究分支机构组成，即流行病学、生物统计学和生物信息学，以及 社会科学和行为科学，其使命是设计和实施原创性研究 影响公众健康的高影响力研究结果的可能性。 根据健康与疾病发育起源(DOHAD)假说，早期生命暴露可以通过细胞对生物过程的适应，对个人的健康和慢性病风险进行编程。产前暴露和遗传因素影响胎儿生长发育和新生儿健康，这是终身健康和疾病的重要决定因素。我们提出了一种方法来检查a)父亲的角色，b)胎盘决定因素，以及c)分娩时机与胎儿和新生儿的健康和发育的关系。将进行一项队列研究，以收集大约10,728名孕妇及其新生儿和大约3825名男性伴侣的共同数据元素，并对妊娠期糖尿病妇女进行随机试验(大约 妇女3450人，增加2730人)。非洲裔美国女性将被过度抽样(约4250人)。预计将建立多个研究地点。

The Division of Intramural Population Health Research (DIPHR) at the Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) designs and conducts original epidemiological, behavioral, and biostatistical research encompassing several research domains such as human reproduction and development, pregnancy and related complications, pediatric and adolescent health and behaviors, and methodologic research relevant for our mission. The Division comprises three intramural research branches, Epidemiology, Biostatistics & Bioinformatics, and Social and Behavioral Sciences, and its mission is to design and implement original research with the potential for high impact findings that impact public health. Under the developmental origins of health and disease (DOHaD) hypothesis, early life exposures can “program” an individual for health and chronic disease risk through cellular adaptations to biological processes. Prenatal exposures and genetic factors impact fetal growth and development and neonatal health, important determinants of life-long health and disease. We propose an approach to examine a) the father’s role, b) placental determinants, and c) timing of delivery in relation to fetal and neonatal health and development. A cohort study will be performed to collect common data elements from approximately 10,728 pregnant women and their neonates and approximately 3825 male partners with a randomized trial conducted in women with gestational diabetes (approximately 3450 women, an addition of 2730). African American women will be oversampled (~4250). It is anticipated that multiple study sites will be established.